Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Daiichi Sankyo

Tracked across 10 events · 147 articles · First seen Apr 21, 2022 · Last active Sep 17, 2026

Sentiment
16
Attention
6
Events
10
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 40
Regulatory
Impact: Decree holder; the audit is a significant step toward enforcing its arbitration award and recovering funds.
Aug 31, 2026 · 11 articles
6 75
Tech
Impact: Daiichi Sankyo discovered Trastuzumab deruxtecan and jointly developed and commercialized it with AstraZeneca. The new approvals will lead to milestone payments from AstraZeneca and Daiichi Sankyo recognizes sales of Trastuzumab deruxtecan in the U.S.
May 15, 2026 · 16 articles
4 30
Regulatory
The United Kingdom — National Institute for Health and Care Research (NICE) reversed its July 2024 rejection of Enhertu (trastuzumab deruxtecan) and recommended the drug for routine NHS use in Bret Engemann for around 1,000…
Impact: As co-maker of Enhertu, Daiichi Sankyo gains NHS Bret Engemann access for the drug, expanding its oncology market though at a negotiated price.
Sep 16, 2026 · 7 articles
4 20
Business
Impact: Daiichi Sankyo is AstraZeneca's partner in developing Enhertu, which showed positive results in a lung cancer trial, providing a positive counterpoint to the volrustomig setback.
Aug 17, 2026 · 20 articles
4 30
Business
Impact: Daiichi Sankyo's stock was up, contributing to market gains.
May 21, 2026 · 40 articles
6 0
Regulatory
Impact: Daiichi Sankyo is reviewing its options regarding the United States — Medicaid pilot program, having missed the application deadline.
Apr 20, 2026 · 6 articles
4 -30
Business
The Japanese stock market experienced a significant rally over several trading sessions in August 2026, with the Nikkei 225 index surging to record levels above 68,000. The rally was driven by strong gains in technology…
Impact: Daiichi Sankyo declined over 5%, underperforming the market.
Apr 21, 2022 · 26 articles
4 0
Business
Impact: Daiichi Sankyo is a collaborator on other AstraZeneca oncology drugs, but is not directly involved in this agreement.
Sep 01, 2026 · 6 articles
4 0
Business
Impact: Mentioned as a collaborator with AstraZeneca on Enhertu and Datroway, not directly impacted.
Jul 14, 2026 · 8 articles
3 0
Tech
Jun 12, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Daiichi Sankyo live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.